
Chinese General Practice ›› 2023, Vol. 26 ›› Issue (35): 4419-4424.DOI: 10.12114/j.issn.1007-9572.2023.0261
• Article • Previous Articles Next Articles
Received:2023-03-09
Revised:2023-06-24
Published:2023-12-15
Online:2023-07-18
Contact:
REN Huiling
通讯作者:
任慧玲
作者简介:基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0261
| 组别 | 例数 | 年龄(岁) | 性别(男/女) | 吸烟〔例(%)〕 | 饮酒〔例(%)〕 | 脑卒中史〔例(%)〕 | 高血压〔例(%)〕 | 高脂血症〔例(%)〕 | 糖尿病〔例(%)〕 | 冠心病〔例(%)〕 | 入院NIHSS评分〔M(P25,P75),分〕 | FBG〔M(P25,P75),mmol/L〕 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| END组 | 45 | 62.5±12.1 | 30/15 | 16(35.6) | 16(35.6) | 14(31.1) | 36(80.0) | 26(57.8) | 25(55.6) | 8(17.8) | 2(1,3) | 6.70(5.60,8.50) |
| 非END组 | 152 | 63.9±11.8 | 94/58 | 47(30.9) | 44(28.9) | 27(17.8) | 123(80.9) | 64(42.1) | 59(38.8) | 28(18.4) | 2(1,3) | 5.70(4.90,6.93) |
| 检验统计量值 | 0.724a | 0.346b | 0.343b | 0.716b | 3.754b | 0.019b | 3.437b | 3.978b | 0.010b | -0.886 | -2.954 | |
| P值 | 0.470 | 0.556 | 0.558 | 0.398 | 0.053 | 0.891 | 0.064 | 0.046 | 0.922 | 0.376 | 0.003 | |
| 组别 | TC〔M(P25,P75),mmol/L〕 | TG〔M(P25,P75),mmol/L〕 | HDL〔M(P25,P75),mmol/L〕 | LDL〔M(P25,P75),mmol/L〕 | Hcy〔M(P25,P75),μmol/L〕 | TyG指数〔M(P25,P75)〕 | 梗死部位〔例(%)〕 | |||||
| 基底节区 | 半卵圆中心 | 脑干 | ||||||||||
| END组 | 4.76(3.91,5.37) | 1.55(1.19,2.12) | 1.11(0.96,1.26) | 2.86(2.27,3.33) | 14.10(11.25,17.95) | 8.76(8.47,9.08) | 17(37.8) | 13(28.9) | 15(33.3) | |||
| 非END组 | 4.43(3.71,5.25) | 1.24(0.89,1.87) | 1.08(0.94,1.27) | 2.69(2.17,3.24) | 14.05(11.08,18.35) | 8.37(7.95,8.82) | 69(45.4) | 34(22.4) | 49(32.2) | |||
| 检验统计量值 | -1.081 | -2.244 | -0.160 | -0.826 | -0.007 | -3.230 | 1.093b | |||||
| P值 | 0.280 | 0.025 | 0.873 | 0.409 | 0.994 | 0.001 | 0.579 | |||||
Table 1 Comparison of clinical data of patients in the END group and non-END group
| 组别 | 例数 | 年龄(岁) | 性别(男/女) | 吸烟〔例(%)〕 | 饮酒〔例(%)〕 | 脑卒中史〔例(%)〕 | 高血压〔例(%)〕 | 高脂血症〔例(%)〕 | 糖尿病〔例(%)〕 | 冠心病〔例(%)〕 | 入院NIHSS评分〔M(P25,P75),分〕 | FBG〔M(P25,P75),mmol/L〕 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| END组 | 45 | 62.5±12.1 | 30/15 | 16(35.6) | 16(35.6) | 14(31.1) | 36(80.0) | 26(57.8) | 25(55.6) | 8(17.8) | 2(1,3) | 6.70(5.60,8.50) |
| 非END组 | 152 | 63.9±11.8 | 94/58 | 47(30.9) | 44(28.9) | 27(17.8) | 123(80.9) | 64(42.1) | 59(38.8) | 28(18.4) | 2(1,3) | 5.70(4.90,6.93) |
| 检验统计量值 | 0.724a | 0.346b | 0.343b | 0.716b | 3.754b | 0.019b | 3.437b | 3.978b | 0.010b | -0.886 | -2.954 | |
| P值 | 0.470 | 0.556 | 0.558 | 0.398 | 0.053 | 0.891 | 0.064 | 0.046 | 0.922 | 0.376 | 0.003 | |
| 组别 | TC〔M(P25,P75),mmol/L〕 | TG〔M(P25,P75),mmol/L〕 | HDL〔M(P25,P75),mmol/L〕 | LDL〔M(P25,P75),mmol/L〕 | Hcy〔M(P25,P75),μmol/L〕 | TyG指数〔M(P25,P75)〕 | 梗死部位〔例(%)〕 | |||||
| 基底节区 | 半卵圆中心 | 脑干 | ||||||||||
| END组 | 4.76(3.91,5.37) | 1.55(1.19,2.12) | 1.11(0.96,1.26) | 2.86(2.27,3.33) | 14.10(11.25,17.95) | 8.76(8.47,9.08) | 17(37.8) | 13(28.9) | 15(33.3) | |||
| 非END组 | 4.43(3.71,5.25) | 1.24(0.89,1.87) | 1.08(0.94,1.27) | 2.69(2.17,3.24) | 14.05(11.08,18.35) | 8.37(7.95,8.82) | 69(45.4) | 34(22.4) | 49(32.2) | |||
| 检验统计量值 | -1.081 | -2.244 | -0.160 | -0.826 | -0.007 | -3.230 | 1.093b | |||||
| P值 | 0.280 | 0.025 | 0.873 | 0.409 | 0.994 | 0.001 | 0.579 | |||||
| 指标 | β | SE | Wald χ2值 | OR | 95%CI | P值 |
|---|---|---|---|---|---|---|
| TyG指数 | 0.546 | 0.275 | 3.952 | 1.726 | (1.008,2.956) | 0.047 |
| 年龄 | -0.002 | 0.016 | 0.021 | 0.998 | (0.966,1.030) | 0.885 |
| 性别 | 0.290 | 0.391 | 0.549 | 1.336 | (0.621,2.875) | 0.459 |
| 糖尿病 | 0.447 | 0.373 | 1.433 | 1.563 | (0.752,3.249) | 0.231 |
Table 2 Multivariate Logistic regression analysis of influencing factors for early neurological deterioration in SSI patients
| 指标 | β | SE | Wald χ2值 | OR | 95%CI | P值 |
|---|---|---|---|---|---|---|
| TyG指数 | 0.546 | 0.275 | 3.952 | 1.726 | (1.008,2.956) | 0.047 |
| 年龄 | -0.002 | 0.016 | 0.021 | 0.998 | (0.966,1.030) | 0.885 |
| 性别 | 0.290 | 0.391 | 0.549 | 1.336 | (0.621,2.875) | 0.459 |
| 糖尿病 | 0.447 | 0.373 | 1.433 | 1.563 | (0.752,3.249) | 0.231 |
| 项目 | 基底节区 | 半卵圆中心 | ||||
|---|---|---|---|---|---|---|
| OR | 95%CI | P值 | OR | 95%CI | P值 | |
| TyG指数 | 3.164 | (1.290,7.760) | 0.012 | 0.844 | (0.274,2.603) | 0.768 |
| 年龄 | 0.982 | (0.927,1.041) | 0.544 | 0.929 | (0.861,1.002) | 0.058 |
| 糖尿病 | 1.330 | (0.398,4.445) | 0.643 | 0.968 | (0.221,4.241) | 0.965 |
| 男性 | 0.522 | (0.129,2.119) | 0.363 | 1.350 | (0.291,6.261) | 0.702 |
| 脑卒中史 | 4.521 | (0.835,24.480) | 0.080 | 1.393 | (0.315,6.149) | 0.662 |
Table 3 Multivariate Logistic regression analysis of influencing factors for early neurological deterioration in patients with SSI at different infarction areas
| 项目 | 基底节区 | 半卵圆中心 | ||||
|---|---|---|---|---|---|---|
| OR | 95%CI | P值 | OR | 95%CI | P值 | |
| TyG指数 | 3.164 | (1.290,7.760) | 0.012 | 0.844 | (0.274,2.603) | 0.768 |
| 年龄 | 0.982 | (0.927,1.041) | 0.544 | 0.929 | (0.861,1.002) | 0.058 |
| 糖尿病 | 1.330 | (0.398,4.445) | 0.643 | 0.968 | (0.221,4.241) | 0.965 |
| 男性 | 0.522 | (0.129,2.119) | 0.363 | 1.350 | (0.291,6.261) | 0.702 |
| 脑卒中史 | 4.521 | (0.835,24.480) | 0.080 | 1.393 | (0.315,6.149) | 0.662 |
| 组别 | 例数 | 年龄(岁) | 性别(男/女) | 吸烟〔例(%)〕 | 饮酒〔例(%)〕 | 脑卒中史〔例(%)〕 | 高血压〔例(%)〕 | 高脂血症〔例(%)〕 | 糖尿病〔例(%)〕 |
|---|---|---|---|---|---|---|---|---|---|
| TyG指数<8.61者 | 111 | 65.6±11.9 | 74/37 | 36(32.4) | 34(30.6) | 26(23.4) | 89(80.2) | 27(24.3) | 33(29.7) |
| TyG指数≥8.61者 | 86 | 60.9±11.2 | 50/36 | 27(31.4) | 26(30.2) | 15(17.4) | 70(81.4) | 63(93.3) | 51(59.3) |
| 检验统计量值 | 2.893a | 1.511b | 0.024b | 0.004b | 1.052b | 0.046b | 46.756b | 17.326b | |
| P值 | 0.004 | 0.219 | 0.877 | 0.952 | 0.305 | 0.830 | <0.001 | <0.001 | |
| 组别 | 冠心病〔例(%)〕 | 入院NIHSS评分〔M(P25,P75),分〕 | FBG〔M(P25,P75),mmol/L〕 | TC(mmol/L) | TG〔M(P25,P75),mmol/L〕 | HDL〔M(P25,P75),mmol/L〕 | |||
| TyG指数<8.61者 | 23(20.7) | 2.00(0.75,3.00) | 5.40(4.80,6.10) | 4.29±0.96 | 1.01(0.77,1.26) | 1.11(0.96,1.33) | |||
| TyG指数≥8.61者 | 13(15.1) | 2.00(1.00,3.00) | 7.20(5.98,9.23) | 4.99±1.31 | 1.99(1.61,2.64) | 1.05(0.92,1.18) | |||
| 检验统计量值 | 1.019b | -0.627 | -6.990 | -4.274a | -10.350 | -2.226 | |||
| P值 | 0.313 | 0.531 | <0.001 | <0.001 | <0.001 | 0.026 | |||
| 组别 | LDL〔M(P25,P75),mmol/L〕 | Hcy〔M(P25,P75),μmol/L〕 | 梗死部位〔例(%)〕 | END〔例(%)〕 | |||||
| 基底节区 | 半卵圆中心 | 脑干 | |||||||
| TyG指数<8.61者 | 2.54(2.10,3.07) | 14.50(12.05,18.30) | 47(42.3) | 32(28.8) | 32(28.8) | 14(12.6) | |||
| TyG指数≥8.61者 | 3.00(2.33,3.46) | 12.90(10.60,17.75) | 39(45.3) | 15(17.4) | 32(37.2) | 31(36.0) | |||
| 检验统计量值 | -3.606 | -1.489 | 3.781b | 15.098b | |||||
| P值 | <0.001 | 0.136 | 0.151 | <0.001 | |||||
Table 4 Comparison of clinical data between patients with TyG index <8.61 and patients with TyG index ≥8.61
| 组别 | 例数 | 年龄(岁) | 性别(男/女) | 吸烟〔例(%)〕 | 饮酒〔例(%)〕 | 脑卒中史〔例(%)〕 | 高血压〔例(%)〕 | 高脂血症〔例(%)〕 | 糖尿病〔例(%)〕 |
|---|---|---|---|---|---|---|---|---|---|
| TyG指数<8.61者 | 111 | 65.6±11.9 | 74/37 | 36(32.4) | 34(30.6) | 26(23.4) | 89(80.2) | 27(24.3) | 33(29.7) |
| TyG指数≥8.61者 | 86 | 60.9±11.2 | 50/36 | 27(31.4) | 26(30.2) | 15(17.4) | 70(81.4) | 63(93.3) | 51(59.3) |
| 检验统计量值 | 2.893a | 1.511b | 0.024b | 0.004b | 1.052b | 0.046b | 46.756b | 17.326b | |
| P值 | 0.004 | 0.219 | 0.877 | 0.952 | 0.305 | 0.830 | <0.001 | <0.001 | |
| 组别 | 冠心病〔例(%)〕 | 入院NIHSS评分〔M(P25,P75),分〕 | FBG〔M(P25,P75),mmol/L〕 | TC(mmol/L) | TG〔M(P25,P75),mmol/L〕 | HDL〔M(P25,P75),mmol/L〕 | |||
| TyG指数<8.61者 | 23(20.7) | 2.00(0.75,3.00) | 5.40(4.80,6.10) | 4.29±0.96 | 1.01(0.77,1.26) | 1.11(0.96,1.33) | |||
| TyG指数≥8.61者 | 13(15.1) | 2.00(1.00,3.00) | 7.20(5.98,9.23) | 4.99±1.31 | 1.99(1.61,2.64) | 1.05(0.92,1.18) | |||
| 检验统计量值 | 1.019b | -0.627 | -6.990 | -4.274a | -10.350 | -2.226 | |||
| P值 | 0.313 | 0.531 | <0.001 | <0.001 | <0.001 | 0.026 | |||
| 组别 | LDL〔M(P25,P75),mmol/L〕 | Hcy〔M(P25,P75),μmol/L〕 | 梗死部位〔例(%)〕 | END〔例(%)〕 | |||||
| 基底节区 | 半卵圆中心 | 脑干 | |||||||
| TyG指数<8.61者 | 2.54(2.10,3.07) | 14.50(12.05,18.30) | 47(42.3) | 32(28.8) | 32(28.8) | 14(12.6) | |||
| TyG指数≥8.61者 | 3.00(2.33,3.46) | 12.90(10.60,17.75) | 39(45.3) | 15(17.4) | 32(37.2) | 31(36.0) | |||
| 检验统计量值 | -3.606 | -1.489 | 3.781b | 15.098b | |||||
| P值 | <0.001 | 0.136 | 0.151 | <0.001 | |||||
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
曹志伟,刘倩,李静,等. 三酰甘油血糖指数纵向轨迹对新发心脑血管疾病的影响研究[J]. 中国全科医学,2022,25(5):554-560,567. DOI:10.12114/j.issn.1007-9572.2021.01.320.
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [1] | DU Huijie, YANG Xuezhi, LIU Zuting, LIU Xingyu, ZHANG Huiqin, LUO Tian, YANG Xia, LIU Song, KUANG Jie. One-year Recurrence Risk Prediction in Large Artery Atherosclerotic Acute Ischemic Stroke Using Random Survival Forest [J]. Chinese General Practice, 2026, 29(31): 4619-4626. |
| [2] | ZHAN Daowei, WEI Xuwang, HU Minlei, XU Yingmei, YANG Xibing, LUO Kaitao. Effect of Acupuncture Combined with Tirofiban on Early Neurological Deterioration in Patients with Ischemic Stroke after Thrombolysis: a Randomized Controlled Trial [J]. Chinese General Practice, 2026, 29(29): 4241-4247. |
| [3] | ZHANG Boyu, XU Bo, LI Jianguo, YIN He, LUO Pengren, WANG Haojie, JIN Zhefeng, ZHU Liguo. Research on the Diagnostic Value of Rasterstereography for Angles Related to Adolescent Idiopathic Scoliosis [J]. Chinese General Practice, 2026, 29(24): 3434-3439. |
| [4] | SUN Qinyu, YANG Tianxiao, DENG Yifan, FANG Zhen, JI Jun, HE Shenghu, ZHANG Jing. Analysis of the Correlation between Different Surrogate Indicators of Insulin Resistance and the Occurrence of MACEs after PCI in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease and Coronary Heart Disease [J]. Chinese General Practice, 2026, 29(22): 3146-3153. |
| [5] | HAN Yue, BIAN Zhe, GU Haochen, WANG Dali, PENG Yanbo. Impact of Cumulative Defined Daily Dose of Statins on Recurrence Risk in Ischemic Stroke Patients [J]. Chinese General Practice, 2026, 29(14): 1821-1826. |
| [6] | CHEN Yiming, HUANG Yiling, JI Fei, LYU Ling, HUANG Yu, WU Zeyu, HANG Qiqi, PING Fan, YANG Meng. Hepatic-glycemic Interdependence: the Bidirectional Relationship between Type 2 Diabetes and MASLD and Emerging Therapeutic Strategies [J]. Chinese General Practice, 2026, 29(12): 1497-1504. |
| [7] | LIU Yang, LIANG Fang, WU Ling, LI Wenlei, LI Pengfei. Diagnostic Value of Non-conventional Lipids and the Triglyceride-glucose Index in First-onset Acute Ischemic Stroke [J]. Chinese General Practice, 2026, 29(11): 1422-1429. |
| [8] | SUN Qinyu, DENG Yifan, YANG Tianxiao, FANG Zhen, JI Jun, HE Shenghu, ZHANG Jing. Clinical Study of HbA1c/ApoA-1, TyG-BMI and Their Combination to Predict the Severity of Coronary Artery Calcification [J]. Chinese General Practice, 2026, 29(09): 1137-1145. |
| [9] | CAO Lei, LIU Xuechun, JIANG Wei, CHEN Yan, YAN Sunhong, DU Jing. Study on the Prediction of Muscle Attenuation in Patients with Acute Ischemic Stroke by the Cross-sectional Area and Thickness of the Temporalis Muscle [J]. Chinese General Practice, 2026, 29(08): 997-1007. |
| [10] | SHENG Luguang, LIU Dandan, LIU Weibin, LU Jun, LEI Tao, CHEN Qingguang, LU Hao, XU Bilin. Effects of Short-term Dietary Intervention for Obese Patients with Abnormal Glucose Metabolism [J]. Chinese General Practice, 2026, 29(03): 373-379. |
| [11] | ZHOU Qianmei, MIAO Kali, ZHONG Yongming, ZHANG Fuman, ZHANG Zhe, LI Chengyi. Gas6 Expression in Breast Cancer and Correlation with Clinical Pathological Features and Prognosis [J]. Chinese General Practice, 2025, 28(35): 4449-4456. |
| [12] | MI Lingyu, CHEN Lianxin, GAO Hengbo, WANG Bincheng. Predictive Value of Triglyceride-glucose Index for Prognosis in Patients with Pulmonary Embolism [J]. Chinese General Practice, 2025, 28(35): 4421-4429. |
| [13] | CHEN Huiyu, XU Ziyan, LI Yuhong. Correlation between Dietary Inflammatory Index and Delayed Onset of Lactogenesis in Women of the Third Trimester [J]. Chinese General Practice, 2025, 28(35): 4442-4448. |
| [14] | WANG Biyou, GAO Ying, YOU Junfang, LIU Li, ZHANG Qing, SU Haiyan. Canonical Correlation Analysis of Lipid Ratios and Inflammatory Markers in Individuals at Risk of Cardiovascular Disease [J]. Chinese General Practice, 2025, 28(33): 4132-4139. |
| [15] | YANG Jian, WU Chuan'an, ZHOU Hairong, TIAN Feng, CHI Chunhua. Diagnostic Value of the Triglyceride Glucose-body Mass Index for Type 2 Diabetes Mellitus Combined with Metabolic Dysfunction-associated Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(32): 4075-4081. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||